Table 1 Characteristics and Medication usage of patients with diabetes and CKD

Age (SD)

66.9 (11.0)

Male/Female (%)

214 (69.5)/94 (30.5)

Main language spoken at home (% English)

238/305 (78.0)

Australia as the country of birth

141/304 (46.4)

Body weight (IQR) kg

86.1 (72.8 – 101.3)

Height (SD) m

1.68 (0.10)

BMI (SD) kg/m²

30.7 (7.4)

Systolic blood pressure (SD) mmHg

134 (18)

Diastolic blood pressure (SD) mmHg

72 (11)

Active Smoker (%)

18/230 (7.8)

Diabetes duration (IQR) yrs.

17.0 (10.0 – 23.5)

 type 1

28 (9.1)

 type 2

271 (88.0)

 other

9 (2.9)

 3a

72 (23.4)

 3b

79 (25.7)

 4

76 (24.7)

 5 (inclusive of 5D)

81 (26.3)

Dialysis (%)

59 (19.2)

 Haemodialysis (%)

42 (71.1)

 Peritoneal dialysis (%)

17 (28.9)

 Hypertension (%)

291/308 (94.5)

 Dyslipidaemia (%)

256/308 (83.1)

 Ischemic Heart Disease (%)

143/304 (47.0)

 Stroke (%)

38/305 (12.5)

 Peripheral Vascular Disease (%)

82/304 (27.0)

 Diabetic Retinopathy (%)

132/305 (43.3)

 Diabetic Neuropathy (%)

108/305 (35.4)

 Diabetic Nephropathy as a cause of CKD (%)

219/306 (71.6)

 Haemoglobin (SD) g/L

122 (18)

 HbA1c %

7.3 (6.4 – 8.3)

 HbA1c (mmol/mol)

56 (47 – 67)

 Total Cholesterol (IQR) mmol/L

3.9 (3.4 – 4.6)

 LDL (IQR) mmol/L

1.8 (1.4 – 2.5)

 HDL (IQR) mmol/L

1 (0.8 – 1.2)

 Triglycerides (IQR) mmol/L

1.8 (1.2 – 2.5)

 Potassium (SD) mmol/L

4.6 (0.6)

 Calcium (SD) mmol/L

2.31 (0.14)

 Phosphate (IQR) mmol/L

1.23 (1.08 – 1.46)

 PTH (IQR) pmol/L

15.7 (7.8 – 30.6)

 Insulin only (%)

136 (44.2)

 Non-insulin glucose lowering therapy only (%)

85 (27.6)

 Both insulin and non-insulin glucose lowering therapy (%)

67 (21.8)

 Diet only with other glucose lowering therapies (%)

20 (6.5)

 Statin use (%)

248 (80.5)

 Fibrate (%)

34 (11.0)

 Use of any antihypertensive (%)

278 (90.3)

 Use of ACEI and/or AT2RB (%)

185 (60.1)

 Use of other antihypertensive besides an ACEI/AT2RB (%)

240 (77.9)

 ESA use (%)

64 (20.8)

 Iron supplementation (%)

57 (18.5)

 Phosphate binder (%)

58 (18.8)